Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Kyle A Beckwith"'
Autor:
Erin Hertlein, Kyle A Beckwith, Gerard Lozanski, Timothy L Chen, William H Towns, Amy J Johnson, Amy Lehman, Amy S Ruppert, Brad Bolon, Leslie Andritsos, Arletta Lozanski, Laura Rassenti, Weiqiang Zhao, Tiina M Jarvinen, Leigha Senter, Carlo M Croce, David E Symer, Albert de la Chapelle, Nyla A Heerema, John C Byrd
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76607 (2013)
Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatmen
Externí odkaz:
https://doaj.org/article/6701b5761778490aa7e468949244dd8d
Autor:
Seema A. Bhat, Adam Kittai, Kyle A. Beckwith, Cecelia R. Miller, Ying Huang, Daniel Goldstein, Jennifer A. Woyach, Kerry A. Rogers, Lynne V. Abruzzo, Amy S. Ruppert, Michael R. Grever, John C. Byrd, David A. Bond, Nyla A. Heerema
Publikováno v:
Blood. 138:2372-2382
Complex karyotype, defined as ≥3 cytogenetic abnormalities, is prognostic of survival in patients treated with ibrutinib or venetoclax in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). Recent studies re-evaluating this dichotomous var
Autor:
Adam S. Kittai, Ying Huang, Kyle A. Beckwith, Seema A. Bhat, David A. Bond, John C. Byrd, Daniel Goldstein, Michael R. Grever, Cecelia Miller, Kerry A. Rogers, Max Yano, Jennifer A. Woyach
Publikováno v:
American journal of hematologyREFERENCES.
Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited data evaluating risk of RT in patients treated with ibrutinib. We performed a retrospective an
Autor:
Priscilla Do, Erin Hertlein, Minh Tran, Rosa Lapalombella, Carolyn Cheney, Natarajan Muthusamy, Larry Beaver, Brittany G. Griffin, Yang Liu, Kyle A. Beckwith, Xiaokui Mo, John C. Byrd
Publikováno v:
J Immunol
The clinical benefit of CTLA-4 blockade on T cells is known, yet the impact of its expression on cancer cells remains unaddressed. We define an immunosuppressive role for tumor-expressed CTLA-4 using chronic lymphocytic leukemia (CLL) as a disease mo
Autor:
Ashleigh Keiter, Seema A. Bhat, Adam Kittai, Daniel Goldstein, Kerry A. Rogers, Michael R. Grever, Kyle A. Beckwith, David A. Bond, John C. Byrd, Ying Huang, Jennifer A. Woyach
Publikováno v:
Blood. 138:3731-3731
Background: Aggressive lymphoma arising in the setting of chronic lymphocytic leukemia (CLL), known as Richter's syndrome (RS), is associated with poor outcomes with standard of care therapies. There is limited capacity for PET-CT to distinguish pati
Autor:
Daniel Goldstein, Kerry A. Rogers, Michael R. Grever, Cecelia R. Miller, Lynne V. Abruzzo, Jennifer A. Woyach, Kyle A. Beckwith, Ying Huang, Amy S. Ruppert, David A. Bond, John C. Byrd, Seema A. Bhat, Adam Kittai, Nyla A. Heerema
Publikováno v:
Blood. 136:2-3
Introduction: Our group and others have previously shown that the presence of complex karyotype (>/= 3 cytogenetic abnormalities) is an important prognostic factor in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) patients treated with i
Autor:
Ping Wei, Dana M. McTigue, Kaitlyn Braun, Phillip G. Popovich, John C. Gensel, Yan Wang, Zhen Guan, Kyle A. Beckwith
Publikováno v:
Journal of Neuroscience. 35:9966-9976
Spinal cord injury (SCI) activates macrophages, endowing them with both reparative and pathological functions. The mechanisms responsible for these divergent functions are unknown but are likely controlled through stochastic activation of different m
Autor:
Kami J. Maddocks, Jeffrey A. Jones, Jennifer A. Woyach, Ching-Shih Chen, Erin Hertlein, Farrukh T. Awan, Kyle A. Beckwith, Ta-Ming Liu, Leslie A. Andritsos, Santosh B. Salunke, Amy Lehman, John C. Byrd, Mitch A. Phelps, Jessica MacMurray, Yuh Ying Yeh, Yonghua Ling, Amy J. Johnson, Xiaoli Zhang
Publikováno v:
Blood. 125:284-295
Aberrant regulation of endogenous survival pathways plays a major role in progression of chronic lymphocytic leukemia (CLL). Signaling via conjugation of surface receptors within the tumor environmental niche activates survival and proliferation path
Autor:
Joseph M. Flynn, John C. Byrd, Kami J. Maddocks, Jennifer A. Woyach, Amy Lehman, Kyle A. Beckwith, Carl H. June, Natarajan Muthusamy, Joseph A. Fraietta, Leslie A. Andritsos, Amber Gordon, Bethany L. Mundy, Jeffrey A. Jones, Carolyn Cheney, Farrukh T. Awan, Marcela V. Maus, Priscilla Do, Amy J. Johnson, Michael A. Caligiuri, Meixiao Long
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f34b58ee36a683b5530dfb645e98da05
https://europepmc.org/articles/PMC5531425/
https://europepmc.org/articles/PMC5531425/
Autor:
Kami J. Maddocks, Carolyn Cheney, Gerard Lozanski, Carlo M. Croce, Leslie A. Andritsos, William H. Towns, Jeffrey A. Jones, Matthew R. Stefanovski, Frank Frissora, Jutta Deckert, Natarajan Muthusamy, Joseph M. Flynn, John C. Byrd, Kyle A. Beckwith, Xiaokui Mo
Publikováno v:
Leukemia
Therapeutic regimens for chronic lymphocytic leukemia (CLL) have increasingly utilized monoclonal antibodies since the chimeric anti-CD20 antibody rituximab was introduced. Despite improved clinical outcomes, current CLL therapies are not curative. T